Compare · UPH vs WGS
UPH vs WGS
Side-by-side comparison of UpHealth Inc. (UPH) and GeneDx Holdings Corp. (WGS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both UPH and WGS operate in Retail: Computer Software & Peripheral Equipment (Technology), so they compete in similar markets.
- WGS is the larger of the two at $2.61B, about 9.5x UPH ($274.1M).
- WGS has hit the wire 8 times in the past 4 weeks while UPH has been quiet.
- WGS has more recent analyst coverage (8 ratings vs 4 for UPH).
- Company
- UpHealth Inc.
- GeneDx Holdings Corp.
- Price
- -
- -
- Market cap
- $274.1M
- $2.61B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Retail: Computer Software & Peripheral Equipment
- Retail: Computer Software & Peripheral Equipment
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 0
- 8
- Recent ratings
- 4
- 8
UpHealth Inc.
UpHealth, Inc. operates as a digital health services company. It provides patient-centric digital health platform and tech-enabled services to manage health and integrate care. The company's solutions include Syntranet Core Platform, an integrated care management platform; Global Telemedicine; MedQuest Digital Pharmacy, a full-service pharmacy that offers manufactured medication, custom compounded medications, nutraceuticals, lab testing, advocacy, education, etc.; and Behavioral Telehealth solutions. It serves empowering providers, health systems, health plans and governments, employers, and educational institutions. The company is based in Delray Beach, Florida.
Latest UPH
- UpHealth Appoints Jay Jennings As Acting CEO; Replacing Martin Beck
- UpHealth Announces CEO Transition and Organizational Changes
- The International Court of Arbitration awarded UpHealth Holdings more than $110 Million in Damages in Breach of Contract Lawsuit Involving the 2020 Purchase by UpHealth of Glocal Healthcare Systems
- UpHealth Completes Sale of Cloudbreak Health at $180 Million Full Cash Deal
- SEC Form DEFA14A filed by UpHealth Inc.
- UpHealth Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form 4 filed by Beck Martin S A
- SEC Form 4 filed by Locke Nathan
- Greene James S was granted 100,000 shares (SEC Form 4)
- Kathuria Chirinjeev was granted 100,000 shares, increasing direct ownership by 3% to 3,955,113 units (SEC Form 4)
Latest WGS
- GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s
- SEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.
- GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
- Amendment: SEC Form SCHEDULE 13G/A filed by GeneDx Holdings Corp.
- GeneDx to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by GeneDx Holdings Corp.
- GeneDx Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- GeneDx Reports Second Quarter 2026 Financial Results
- SEC Form 25-NSE filed by GeneDx Holdings Corp.
- GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026